Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Merck (purified corticotropin gel, corticotropin-zinc hydroxide)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

New drug applications (NDAs) for purified corticotropin gel and corticotropin-zinc hydroxide. Corticotropin gel is a purified corticotropin (ACTH) in a sterile solution of gelatin for prolonged activity. Corticotropin-zinc hydroxide is a sterile aqueous suspension of purified corticotropin (ACTH) with zinc hydroxide for repository action. The products are approved for various disease states including multiple sclerosis, rheumatic disorders, dermatologic diseases, and a variety of collagen, ophthalmic, respiratory diseases as well as allergic and edematous states.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Primary Office
  • 2000 Galloping Hill Road
  • Kenilworth, NJ 07033
  • United States

Merck (purified corticotropin gel, corticotropin-zinc hydroxide) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Merck (purified corticotropin gel, corticotropin-zinc hydroxide)‘s full profile, request access.

Request full access to PitchBook

Merck (purified corticotropin gel, corticotropin-zinc hydroxide) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Merck (purified corticotropin gel, corticotropin-zinc hydroxide)‘s full profile, request access.

Request full access to PitchBook